Inflammatory bowel disease in 2024 and beyond

Richard B Gearry^{1

2}, Cynthia H Seow³, Sreedhar Subramanian⁴

Affiliations

¹ Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
² Department of Gastroenterology, Christchurch Hospital, Christchurch, New Zealand.
³ Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
⁴ Department of Gastroenterology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.

Editorial

Richard B Gearry et al. Aliment Pharmacol Ther. 2024 Nov.

. 2024 Nov;60(9):1164-1165.

doi: 10.1111/apt.18295.

Richard B Gearry^{1

2}, Cynthia H Seow³, Sreedhar Subramanian⁴

¹ Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
² Department of Gastroenterology, Christchurch Hospital, Christchurch, New Zealand.
³ Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
⁴ Department of Gastroenterology, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.

No abstract available

References

1. Allison MC, Pounder RE. Cyclosporin for Crohn's disease. Aliment Pharmacol Ther. 1987;1(1):39–43.
1. Bronze S, Agrawal M, Colombel J‐C, Torres J, Ungaro RC. Review article: prevention of inflammatory bowel disease ‐ the path forward. Aliment Pharmacol Ther. 2024;60:1166–1175.
1. Swaminathan A, Day AS, Sparrow MP, Peyrin‐Biroulet L, Siegel CA, Gearry RB. Review article: measuring disease severity in inflammatory bowel disease—beyond treat to target. Aliment Pharmacol Ther. 2024;60:1176–1199.
1. Riggott C, Ford AC, Gracie DJ. Review article: the role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications. Aliment Pharmacol Ther. 2024;60:1200–1214.
1. Gibson PR, Yao CK, Halmos EP. Review article: evidence‐based dietary management of inflammatory bowel disease. Aliment Pharmacol Ther. 2024;60:1215–1233.